Updates are available Correction dated 2025-07-23

Article History

Accepted: 7 April 2025

First Online: 20 May 2025

Change Date: 23 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40257-025-00972-6

Declarations

:

: Blueprint Medicines Corporation provided funding for the preparation of this article.

: Lauren M. Madigan served on an international advisory board for Blueprint Medicines and participated as a speaker in a non-Continuing Medical Education (CME) session on recognizing and diagnosis mastocytosis; Section editor, JAMA Dermatology. Nathan A. Boggs participated in a Blueprint Medicines-sponsored patient advocacy summit; participated in developing a Blueprint-sponsored webinar for the College of American Pathologists. Anton V. Rets participated in developing a Blueprint Medicines-sponsored webinar for the College of American Pathologists. Alejandro A. Gru is an investigator for Innate Pharma, Stemline Therapeutics, and Dren Bio; a consultant for Blueprint Medicines; and a speaker for Kyowa Kirin. Tsewang Tashi is a member of the advisory board and a primary investigator in Blueprint Medicines clinical trials, Cogent Biosciences, and PharmaEssentia; a member of the study steering committee for Blueprint Medicines clinical trials. David. A Wada and Melody C. Carter have no conflicts of interest that are directly relevant to the content of this article. Scott R. Florell is a consultant for Orlucent Inc.

: Not applicable.

: Not applicable.

: Patients or their representatives provided consent for the publication of any identifiable photographs.

: Not applicable.

: Not applicable.

: All authors contributed to the concept, research, and writing of the manuscript. All authors read and approved the final manuscript.